

PATENT ASSIGNMENT

Electronic Version v1.1  
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
CONVEYING PARTY DATA	
Name	Execution Date
Pfizer, Inc.	10/12/2009
RECEIVING PARTY DATA	
Name:	Monogram Biosciences, Inc.
Street Address:	345 Oyster Point Blvd.
City:	South San Francisco
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 21	
Property Type	Number
Application Number:	10612604
Patent Number:	7553618
Patent Number:	7384734
Patent Number:	7186506
Patent Number:	6653081
Patent Number:	7138231
Patent Number:	6869759
Patent Number:	5837464
Patent Number:	6489098
Patent Number:	7037644
Patent Number:	6351690
Application Number:	10612603
Application Number:	10681078
Application Number:	11052741
Application Number:	10758683

500987061

PATENT  
REEL: 023364 FRAME: 0305

CH \$840.00 10612604

Application Number:	11051812
Application Number:	11092204
Application Number:	10846181
Application Number:	10976721
Application Number:	10989692
Application Number:	11140311

#### CORRESPONDENCE DATA

Fax Number: (703)610-6200

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 703-610-6100

Email: boxip@hhlaw.com

Correspondent Name: Valerie Brennan, Hogan & Hartson L.L.P.

Address Line 1: 7930 Jones Branch Drive

Address Line 2: Box Intellectual Property

Address Line 4: McLean, VIRGINIA 22102

ATTORNEY DOCKET NUMBER:	60482.91
-------------------------	----------

NAME OF SUBMITTER:	Valerie Brennan
--------------------	-----------------

#### Total Attachments: 4

source=Pfizer Patent Release#page1.tif

source=Pfizer Patent Release#page2.tif

source=Pfizer Patent Release#page3.tif

source=Pfizer Patent Release#page4.tif

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Registrant/Applicant:** MONOGRAM BIOSCIENCES, INC.  
**Patents:** SEE ATTACHED EXHIBIT A

**TERMINATION OF PATENT SECURITY INTEREST**

WHEREAS, Monogram Biosciences, Inc., a Delaware corporation (the "**Grantor**"), owns the patents and applications listed on the attached **Exhibit A**, now issued or pending in the United States Patent and Trademark Office (the "**Patents**"); and

WHEREAS, the Grantor entered into that certain Note Security Agreement, dated as of May 5, 2006 (the "**Security Agreement**"), between the Grantor and Pfizer, Inc. ("**Secured Party**"); a true and correct copy of which was recorded by the U.S. Patent and Trademark Office on May 26, 2006 at Reel Number 017681/Frame Number 0183 and Reel Number 017682/Frame Number 0142, respectively.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Secured Party hereby:

1. releases and reassigns to the Grantor any and all liens, security interests, right, title and interest of Secured Party pursuant to the Security Agreement in the patents and applications more fully described on **Exhibit A**, without recourse or representation or warranty, express or implied; and
2. authorizes and requests the Commissioner of Patents and Trademarks of the United States of America to note and record the existence of the release hereby given.

[Signature page follows]

IN WITNESS WHEREOF, Secured Party has caused this Termination of Patent Security Interest to be signed by its duly authorized representatives as of this 12<sup>th</sup> day of ~~September~~ October 2009.

**SECURED PARTY:**

**Pfizer, Inc.**

By: 

Name: DAVID REED

Title: ASSISTANT SECRETARY

Address: 235 East 42<sup>nd</sup> Street

New York, NY 10017

**EXHIBIT A****U.S. PATENTS**

<b>Application No.</b>	<b>Filing Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Title</b>
10/612,604	07/01/03			Compositions and methods for determining the replication capacity of a pathogenic virus
10/612,600	07/01/03	7553618	06/30/09	Methods for determining human immunodeficiency virus type 1 (HIV-1) hypersusceptibility to the protease inhibitor amprenavir
10/367,223	02/13/03	7384734	06/10/08	Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
09/663,458	09/15/00	7186506	03/06/07	Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
09/881,033	06/12/01	6,653,081	11/25/03	Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
09/766,344	01/19/01	7138231	11/21/06	Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
09/591,899	06/12/00	6,869,759	03/22/05	Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
08/790,963	01/29/97	5,837,464	11/17/98	Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
09/339,357	06/23/99	6,489,098	12/03/02	Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
09/320,299	05/26/99	7,037,644	05/02/06	Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
09/489,221	01/21/00	6,351,690	02/26/02	Automated method and system for performing antiviral drug susceptibility and resistance testing
10/612,603	07/01/03			Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
10/681,078	10/07/03			Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
11/052,741	02/04/05			Compositions and methods for determining the replication capacity of a pathogenic virus

<b>Application No.</b>	<b>Filing Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Title</b>
10/758,683	01/14/04			Method of accessing the effectiveness of a non-nucleoside reverse transcriptase inhibitor (NNRTI) on a human immunodeficiency virus type 1 (HIV-1) infected patients
11/051,812	02/04/05			Methods for determining reduced susceptibility of HIV to protease inhibitor treatment
11/092,204	03/28/05			Compositions and methods for determining epistatic relationships between HIV mutations that affect replication capacity
10/846,181	05/14/04	7279279	10/09/07	Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
10/976,721	10/29/04			Methods and compositions for determining resistance or susceptibility of HIV-1 to stavudine
10/989,692	11/15/04			Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
11/140,311	05/27/05			Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decision in the treatment of HIV/AIDS